Jaguar health announces the presentation of findings from the investigator-initiated phase 2 halt-d study of crofelemer for prevention of chemotherapy-induced diarrhea (cid) in breast cancer patients at san antonio breast cancer symposium (sabcs 2021)

Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients san francisco, ca / accesswire / december 10, 2021 / jaguar health, inc. (nasdaq:jagx) and its wholly owned subsidiary napo pharmaceuticals today announced the third-party presentation of findings from the investigator-initiated halt-d trial evaluating crofelemer for preventing chemotherapy-induced diarrhea (cid) in her2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane. these therapies cause cid in up to 80% of breast cancer patients, reaching grade 3, which often requires hospitalization, in 8-12% of patients.
JAGX Ratings Summary
JAGX Quant Ranking